A randomized, multicenter, phase II study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC) Meeting Abstract
| Authors: | Isakoff, S. J.; Kim, S. B.; Im, S. A.; Dent, R. A.; Traina, T. A.; Valero, V.; Saura, C.; Yalamanchili, S.; Patel, P.; Oliveira, M. |
| Abstract Title: | A randomized, multicenter, phase II study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC) |
| Meeting Title: | 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 75 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2014 Dec 9-13 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-05-01 |
| Language: | English |
| ACCESSION: | WOS:000356730200090 |
| DOI: | 10.1158/1538-7445.sabcs14-ot1-1-16 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-1-16 -- 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium -- DEC 09-13, 2014 -- San Antonio, TX -- S -- Source: Wos |
